Jaguar Health Reports First Quarter 2026 Financials
Jaguar Health reported Q1 2026 total net revenue of $20.3 million, an 816% increase year-over-year, driven primarily by a $19.1 million license and grant revenue stream from a new U.S. licensing agreement with Future Pak. The company turned an operating loss of $9.4 million in Q1 2025 into operating income of $10.2 million in Q1 2026, aided by the license revenue and a significant reduction in sales and marketing expenses following the dissolution of its previous sales group. Despite the operational turnaround, Jaguar reported a net loss of $7.0 million for the quarter, with Non-GAAP Recurring EBITDA improving to a loss of $5.1 million from $9.7 million a year earlier.
Key figures
- Revenue
- 20272000
- Revenue Yoy
- 816%
- Ga expense
- 4100000
- R d expense
- 3900000
- License revenue
- 19068000
- Product revenue
- 1204000
- Operating income
- 10182000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.